Kurs
+7,45%
Kalender
Est. tid* | ||
2025-02-25 | - | Bokslutskommuniké 2024 |
2024-11-29 | - | Kvartalsrapport 2024-Q3 |
2024-08-29 | - | Kvartalsrapport 2024-Q2 |
2024-06-28 | - | Årsstämma |
2024-05-31 | - | X-dag ordinarie utdelning CYXO 0.00 SEK |
2024-05-14 | - | Kvartalsrapport 2024-Q1 |
2024-02-27 | - | Bokslutskommuniké 2023 |
2023-10-27 | - | Extra Bolagsstämma 2023 |
2023-10-27 | - | Kvartalsrapport 2023-Q3 |
2023-08-30 | - | Kvartalsrapport 2023-Q2 |
2023-05-31 | - | X-dag ordinarie utdelning CYXO 0.00 SEK |
2023-05-30 | - | Årsstämma |
2023-05-12 | - | Kvartalsrapport 2023-Q1 |
2023-02-17 | - | Bokslutskommuniké 2022 |
2022-10-27 | - | Kvartalsrapport 2022-Q3 |
2022-08-24 | - | Kvartalsrapport 2022-Q2 |
2022-05-17 | - | X-dag ordinarie utdelning CYXO 0.00 SEK |
2022-05-16 | - | Årsstämma |
2022-05-12 | - | Kvartalsrapport 2022-Q1 |
2022-02-22 | - | Bokslutskommuniké 2021 |
2021-11-12 | - | Kvartalsrapport 2021-Q3 |
2021-08-27 | - | Kvartalsrapport 2021-Q2 |
2021-06-04 | - | X-dag ordinarie utdelning CYXO 0.00 SEK |
2021-06-03 | - | Årsstämma |
2021-05-12 | - | Kvartalsrapport 2021-Q1 |
2021-02-12 | - | Bokslutskommuniké 2020 |
2020-11-13 | - | Kvartalsrapport 2020-Q3 |
2020-08-28 | - | Kvartalsrapport 2020-Q2 |
2020-06-05 | - | X-dag ordinarie utdelning CYXO 0.00 SEK |
2020-06-04 | - | Årsstämma |
2020-05-15 | - | Kvartalsrapport 2020-Q1 |
2020-02-14 | - | Bokslutskommuniké 2019 |
2019-11-15 | - | Kvartalsrapport 2019-Q3 |
2019-08-28 | - | Kvartalsrapport 2019-Q2 |
2019-05-27 | - | X-dag ordinarie utdelning CYXO 0.00 SEK |
2019-05-24 | - | Årsstämma |
2019-05-17 | - | Kvartalsrapport 2019-Q1 |
2019-02-14 | - | Bokslutskommuniké 2018 |
2018-11-21 | - | Kvartalsrapport 2018-Q3 |
2018-06-05 | - | Årsstämma |
2018-05-24 | - | X-dag ordinarie utdelning CYXO 0.00 SEK |
2018-05-16 | - | Kvartalsrapport 2018-Q1 |
2018-02-16 | - | Bokslutskommuniké 2017 |
2017-12-11 | - | Extra Bolagsstämma 2017 |
2017-10-25 | - | Kvartalsrapport 2017-Q3 |
2017-08-30 | - | Kvartalsrapport 2017-Q2 |
2017-05-24 | - | X-dag ordinarie utdelning CYXO 0.00 SEK |
2017-05-23 | - | Årsstämma |
2017-05-16 | - | Kvartalsrapport 2017-Q1 |
2017-02-16 | - | Bokslutskommuniké 2016 |
2016-10-28 | - | Kvartalsrapport 2016-Q3 |
2016-08-24 | - | Kvartalsrapport 2016-Q2 |
Beskrivning
Land | Sverige |
---|---|
Sektor | Hälsovård |
Industri | Bioteknik |
Cyxone (publ), a Swedish biotech in autoimmune diseases, announced today that the company's chairman of the board Bert Junno increases his holding in Cyxone by exercise of 100 000 warrants.
Bert Junno, chairman of the board for Cyxone, commented: "Cyxone is currently in a very eventful phase with several milestones on the horizon. The success that the candidates, T20K and Rabeximod, have been able to show so far has made me more convinced of the potential of Cyxone. I see a very bright future for the company, which is why I now choose to expand my private holdings."
Chairman of the board Bert Junno has increased his private holding with subscription of 100.000 shares through the exercise of equal number of warrants of series 03.
Contact
Cyxone AB (publ)
Kjell G. Stenberg, CEO
Phone: +46 (0) 723 816 168
Email: kjell.g.stenberg@cyxone.com
Adelgatan 21
211 22 Malmö, Sweden
About Cyxone
Cyxone AB is a clinical stage biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). The company's drug portfolio is based on two technological pillars in the form of oral molecules and cyclotide-based drugs that inhibit key processes in the body's cells that are typically associated with various immune-related disorders. Cyxone's technologies have the potential to address an unmet need and provide new effective and safe medicines that can improve the quality of life for patients affected by autoimmune diseases. The company has two drug candidates, T20K for MS in clinical phase I program and Rabeximod for RA in clinical phase II program. Cyxone's Certified Adviser on the Nasdaq First North Growth Market is Mangold Fondkommission AB, +46 (0)8-503 015 50, ca@mangold.se.www.cyxone.com